Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04496089 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC(ZIRDAC-JP) | completed | Phase 1 | 6 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 |
| clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01826877 | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer | completed | Phase 1 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02989714 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | completed | Phase 1 / Phase 2 | 13 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT01912820 | Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT03332576 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 37 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02458716 | Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer | completed | Phase 1 | 26 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00121251 | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT03213964 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | completed | Phase 1 | 10 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT01322802 | Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | completed | Phase 1 | 25 | University of WashingtonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT00715182 | A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer | completed | Phase 1 | 87 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01152801 | Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT01646684 | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT02077933 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | completed | Phase 1 | 79 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 8, 2020 | clinicaltrials |
| NCT03774056 | A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | completed | Phase 1 | 43 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03778047 | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | completed | Phase 1 | 10 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01935973 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02472275 | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | completed | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | completed | Phase 1 | 36 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01711515 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00064129 | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02575222 | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | completed | Phase 1 | 79 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT01510119 | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01536054 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02406521 | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2021source: clinicaltrials